These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 31392198)

  • 21. Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: A Spanish cohort.
    Gutiérrez-Rivas E; Bautista J; Vílchez JJ; Muelas N; Díaz-Manera J; Illa I; Martínez-Arroyo A; Olivé M; Sanz I; Arpa J; Fernández-Torrón R; López de Munáin A; Jiménez L; Solera J; Lukacs Z
    Neuromuscul Disord; 2015 Jul; 25(7):548-53. PubMed ID: 25998610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease.
    Savarese M; Torella A; Musumeci O; Angelini C; Astrea G; Bello L; Bruno C; Comi GP; Di Fruscio G; Piluso G; Di Iorio G; Ergoli M; Esposito G; Fanin M; Farina O; Fiorillo C; Garofalo A; Giugliano T; Magri F; Minetti C; Moggio M; Passamano L; Pegoraro E; Picillo E; Sampaolo S; Santorelli FM; Semplicini C; Udd B; Toscano A; Politano L; Nigro V
    Neuromuscul Disord; 2018 Jul; 28(7):586-591. PubMed ID: 29880332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for late-onset Pompe disease in Internal Medicine departments in Spain.
    López-Rodríguez M; Torralba-Cabeza MA; de Pedro IP; Rivera A; Gil RS; Gómez-Belda A; de la Peña JLP; de Los Santos Moreno A; Selva-O'Callaghan A; Gárate IG; García AG; Hurtado R; de Ureta PT; Barba-Romero MÁ; Milisenda JC; Grau-Junyent JM;
    Orphanet J Rare Dis; 2023 Aug; 18(1):256. PubMed ID: 37653444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
    Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
    J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late-onset Pompe disease: what is the prevalence of limb-girdle muscular weakness presentation?
    Lorenzoni PJ; Kay CSK; Higashi NS; D'Almeida V; Werneck LC; Scola RH
    Arq Neuropsiquiatr; 2018 Apr; 76(4):247-251. PubMed ID: 29742245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late Onset Pompe Disease with Novel Mutations and Atypical Phenotypes.
    Chawla T; Preethish-Kumar V; Polavarapu K; Vengalil S; Bardhan M; Puri R; Verma J; Christopher R; Supriya M; Nashi S; Prasad C; Nadeesh B; Nalini A
    J Neuromuscul Dis; 2022; 9(2):261-273. PubMed ID: 34864681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The frequency of late-onset Pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: A multicenter study.
    Ünver O; Hacıfazlıoğlu NE; Karatoprak E; Güneş AS; Sağer G; Kutlubay B; Sözen G; Saltık S; Yılmaz K; Kara B; Türkdoğan D
    Neuromuscul Disord; 2016 Nov; 26(11):796-800. PubMed ID: 27666774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects.
    Toscano A; Rodolico C; Musumeci O
    Ann Transl Med; 2019 Jul; 7(13):284. PubMed ID: 31392196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of adult Pompe disease in patients with proximal myopathic syndrome and undiagnosed muscle biopsy.
    Golsari A; Nasimzadah A; Thomalla G; Keller S; Gerloff C; Magnus T
    Neuromuscul Disord; 2018 Mar; 28(3):257-261. PubMed ID: 29326002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Alarming signs and symptoms in the early diagnostics of late onset Pompe disease: super omnia clinica].
    Nikitin SS; Kurbatov SA; Bredelev VA; Kovalchuk MO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(12):19-24. PubMed ID: 26978490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case Report: Identification of Compound Heterozygous Mutations in a Patient With Late-Onset Glycogen Storage Disease Type II (Pompe Disease).
    Zhang H; Chen J; Zhu Y; Ma X; Zhong W
    Front Neurol; 2022; 13():839263. PubMed ID: 35386406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population.
    Musumeci O; la Marca G; Spada M; Mondello S; Danesino C; Comi GP; Pegoraro E; Antonini G; Marrosu G; Liguori R; Morandi L; Moggio M; Massa R; Ravaglia S; Di Muzio A; Filosto M; Tonin P; Di Iorio G; Servidei S; Siciliano G; Angelini C; Mongini T; Toscano A;
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):5-11. PubMed ID: 25783438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A database for screening and registering late onset Pompe disease in Turkey.
    Gokyigit MC; Ekmekci H; Durmus H; Karlı N; Koseoglu E; Aysal F; Kotan D; Ali A; Koytak PK; Karasoy H; Yaman A; Sengun İS; Sayin R; Tiftikcioglu BI; Soysal A; Tutkavul K; Bayrak AO; Kısabay A; Elci MA; Yayla V; Yılmaz İA; Ozdamar SE; Erdogan C; Tasdemir N; Serdaroglu Oflazer P;
    Neuromuscul Disord; 2018 Mar; 28(3):262-267. PubMed ID: 29395671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onset Pompe Disease (LOPD).
    Parisi D; Musumeci O; Mondello S; Brizzi T; Oteri R; Migliorato A; Ciranni A; Mongini TE; Rodolico C; Vita G; Toscano A
    Front Neurol; 2018; 9():880. PubMed ID: 30405515
    [No Abstract]   [Full Text] [Related]  

  • 35. Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population.
    Lee JH; Shin JH; Park HJ; Kim SZ; Jeon YM; Kim HK; Kim DS; Choi YC
    Neuromuscul Disord; 2017 Jun; 27(6):550-556. PubMed ID: 28433475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease.
    Bevilacqua JA; Guecaimburu Ehuletche MDR; Perna A; Dubrovsky A; Franca MC; Vargas S; Hegde M; Claeys KG; Straub V; Daba N; Faria R; Periquet M; Sparks S; Thibault N; Araujo R
    Orphanet J Rare Dis; 2020 Jan; 15(1):11. PubMed ID: 31931849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale.
    Hundsberger T; Schoser B; Leupold D; Rösler KM; Putora PM
    J Neurol; 2019 Aug; 266(8):2010-2017. PubMed ID: 31104135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective screening of late-onset Pompe disease (LOPD) in patients with non-diagnostic muscle biopsies.
    Meznaric M; Fumic K; Leonardis L
    J Clin Pathol; 2019 Jul; 72(7):468-472. PubMed ID: 30878973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function.
    Gaeta M; Barca E; Ruggeri P; Minutoli F; Rodolico C; Mazziotti S; Milardi D; Musumeci O; Toscano A
    Mol Genet Metab; 2013 Nov; 110(3):290-6. PubMed ID: 23916420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.